KR20090078065A - The composition of improved lactic acid bacteria feed additive and method for manufacturing thereof - Google Patents

The composition of improved lactic acid bacteria feed additive and method for manufacturing thereof Download PDF

Info

Publication number
KR20090078065A
KR20090078065A KR1020080003847A KR20080003847A KR20090078065A KR 20090078065 A KR20090078065 A KR 20090078065A KR 1020080003847 A KR1020080003847 A KR 1020080003847A KR 20080003847 A KR20080003847 A KR 20080003847A KR 20090078065 A KR20090078065 A KR 20090078065A
Authority
KR
South Korea
Prior art keywords
weight
lactic acid
acid bacteria
feed
culture medium
Prior art date
Application number
KR1020080003847A
Other languages
Korean (ko)
Other versions
KR100923226B1 (en
Inventor
최형규
정은용
홍민선
장희주
Original Assignee
(주)이엘티사이언스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)이엘티사이언스 filed Critical (주)이엘티사이언스
Priority to KR1020080003847A priority Critical patent/KR100923226B1/en
Publication of KR20090078065A publication Critical patent/KR20090078065A/en
Application granted granted Critical
Publication of KR100923226B1 publication Critical patent/KR100923226B1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K10/00Animal feeding-stuffs
    • A23K10/10Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135Bacteria or derivatives thereof, e.g. probiotics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • C12N1/205Bacterial isolates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225Lactobacillus
    • C12R2001/23Lactobacillus acidophilus

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Animal Husbandry (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Fodder In General (AREA)

Abstract

A method for manufacturing the lactobacillus preparation composition for a feed additive, and the lactobacillus preparation composition are provided to improve antibacterial effect. A method for manufacturing the lactobacillus preparation composition for a feed additive comprises the steps of adding betaine and yucca extract to the culture solution of lactobacillus at a constant temperature for a certain time to make the culture solution of killed lactobacillus; and spraying the culture solution of killed lactobacillus on an adsorbent to adsorb it, and mixing it with an excipient.

Description

항균효과가 강화된 사료첨가용 유산균제제 와 그 제조방법{The composition of improved Lactic acid bacteria feed additive and Method for manufacturing thereof}The composition of improved Lactic acid bacteria feed additive and Method for manufacturing et al.

본 발명은 항균효과를 강화시킨 사료첨가용 유산균제 및 그 제조방법에 관한 것으로, 특히 통상의 유산균을 일정 시간 배양 후 비테인을 첨가하여 열처리 한 후 유카추출물을 첨가하여 재 배양하는 과정을 2회 반복한 후 사균화 처리하여 여기에 약제학적으로 허용되는 통상의 흡착제에 사균화 배양액을 흡착시킨 후 부형제에 혼합하는 단계를 포함하는 항균효과가 강화된 사료첨가용 유산균제제 및 그 제조방법에 관한 것이다.The present invention relates to a feed lactic acid bacterium for enhancing the antimicrobial effect and a method for manufacturing the same, and in particular, the conventional lactic acid bacteria are cultured for a predetermined time, followed by heat treatment by addition of bitine, followed by two steps of reculturing by adding a yucca extract. The present invention relates to a lactic acid bactericidal agent having an enhanced antimicrobial effect, comprising adsorbing a bactericidal culture solution to a conventional pharmaceutically acceptable adsorbent, and then mixing the same with an excipient and repeating the same. .

생균제(probiotic)란 그리스어의 공생(for life)이라는 의미에서 유래되었으며, 항생제(antibiotic)와는 반대로 생물 상호간에 생명활동 유지에 유익한 관계를 뜻하며, 공생을 의미하는 생태학적 용어 프로바이오시스(probiosis)에서 기원하며, 릴리(Lilly)와 스틸 웰(Stillwell; 1965)등에 의하여 처음 사용되었다. 그 후 많은 연구자들이 생균제에 대한 정의를 하였는데, 파커(Parker; 1974)는 장내 미생물총의 조절을 통해서 숙주에 유리한 영향을 미치는 미생물 및 대사물질이라고 하여 여 기에는 항생제도 같이 포함하여 포괄적인 정의를 하였다. 미쯔오카(Mitsuoka; 1975)와 크라우포드(Crewford; 1979)는 생균제는 적당한 생리작용을 갖는 미생물 또는 배양물이며, 이들을 투여함으로써 장내에서 이상증식된 균에 대하여 길항적으로 작용하고, 불균형의 장내 미생물총을 정상적으로 복귀시키는 것을 보증할 수 있어야 한다고 하였다. 이 후 푸럴(Fuller; 1989)는 생균제란 장내 미생물의 균형을 개선함으로서 숙주에 유익한 작용을 하는 살아있는 미생물이라 정의하였다. 국내에서는 한인규(2000)에 의하여 생균제란 살아있는 유익미생물을 함유한 제제로서 동물의 장내에 정착하여 다른 병원성 미생물과 경쟁적 배제를 통해 유해미생물의 성장을 억제하고 섭취한 사료의 소화와 흡수를 도와줌으로써 동물의 성장을 촉진하고 사료효율을 개선해주는 미생물제제라고 정의하고 있다.Probiotic is derived from the Greek word for life and, in contrast to antibiotic, refers to a beneficial relationship between living organisms and in the ecological term probiosis, meaning symbiosis. It was first used by Lilly and Stillwell (1965). Since then, many researchers have defined probiotics. Parker (1974) is a microbial and metabolite that has beneficial effects on the host through control of the intestinal microflora. It was. Mitsuoka (1975) and Crawford (1979) are probiotics that are microorganisms or cultures with moderate physiological activity, and antagonistically act against antagonistic bacteria in their intestines by administering them. It should be possible to guarantee that the gun is returned to normal. Fuller (1989) later defined probiotics as living microorganisms that benefit the host by improving the balance of intestinal microflora. In Korea, Probiotics are preparations containing live beneficial microorganisms in Korea, and they are settled in the intestines of animals and compete with other pathogenic microorganisms to inhibit the growth of harmful microorganisms and to help digestion and absorption of ingested feed. It is defined as a microbial agent that promotes growth and improves feed efficiency.

생균제는 예전부터 장내의 이상발효, 설사, 소화불량, 변비감소 등에 효과가 인정되어 인체용으로 사용되어 오다가 동물의 장내 환경개선, 생산성 향상, 설사 등 질병 예방 등의 목적으로 다양한 축종에 걸쳐 널리 사용되어 오고 있다. 현재 생균제에 사용되고 있는 미생물로서는 유산균, 고초균, 곰팡이 및 효모 등이 있으며 건강한 가축의 장내에서 분리한 유산균이 일반적으로 널리 사용되고 있다.Probiotics have been recognized for their effects on abnormal fermentation, diarrhea, indigestion, and constipation in the intestine, and have been used for humans. They are widely used in various livestock species for the purpose of improving the intestinal environment, improving productivity, and preventing diarrhea. It has been used. Microorganisms currently used in probiotics include lactic acid bacteria, subtilis bacteria, molds and yeasts, and lactic acid bacteria isolated from the gut of healthy livestock are generally widely used.

1973년도에 Tortuero는 100마리의 닭에게 11일 동안 락토바실루스 아시도필루스(Lactobacillus acidophilus)를 사료에 첨가하여 급여한 결과 증체량이 향상되고 사료효율이 개선되었다고 보고하였으며(Poultry Sci., 52, 197-203) 1982년도에 Watkins 등은 대장균에 감염된 닭에 락토바실루스 아시도필루스(Lactobacillus acidophilus)를 투여시 폐사 마리수가 무투여균에 비하여 많이 감소함을 발견하였 다(Poultry Sci., 61, 1298-1308). 1989년 맹원재 등은 유산균을 돼지에 급여시 증체량이 향상되고 자돈의 설사가 예방되었음을 보고하였다(Korea J. Anim.Sci,. 31, 318-323). 1984년도에 Reddy G.V 등은 유산균인 락토바실루스 아시도필루스(Lactobacillus acidophilus)와 락토바실루스 불가리쿠스(lactobacillus bulgaricus)가 천연 항생제로서 항균력을 발휘한다고 보고하였다(Cultured Dairy Product J. 7-11). 그 후 Binek M 등은 닭의 소화기관으로부터 분리한 유산균이 살모넬라균, 대장균 및 클로스트리디움균에 대한 항균효과가 있음을 입증하였다(Poultry J.Microbiol.2005;54(4) 287-294). Belfiore 등은 유산균 배양시 유산균이 생산하는 항균 펩타이드물질인 박테리오신(bacteriocin), 락토신(lactocin) 및 니신(nisin) 등에 의하여 대장균의 증식이 억제됨을 보고하였으며(Food microbiol, 2007 May ; 24(3) 223-229), Stern NJ 등은 락토바실루스 살리바리우스(Lactobacillus salivarius)가 생산하는 항균펩타이드 물질인 박테리오신(bacteriocin)이 클로스트리디움균을 현저하게 억제한다고 보고하였다(Antimicrob. agents chemother., 2006 Sep ; 50(9) 3111-3116).In 1973, Tortuero reported that dietary supplementation of 100 chickens with Lactobacillus acidophilus for 11 days resulted in increased weight gain and improved feed efficiency (Poultry Sci., 52, 197). In 1982, Watkins et al. Found that Lactobacillus acidophilus was significantly reduced in E. coli-infected chickens compared to non-administered bacteria (Poultry Sci., 61, 1298). -1308). In 1989, Myung-Won Jae et al reported that when lactic acid bacteria were fed to pigs, the gain in body weight was improved and diarrhea in piglets was prevented (Korea J. Anim. Sci ,. 31, 318-323). In 1984, Reddy G.V et al. Reported that Lactobacillus acidophilus and Lactobacillus bulgaricus exerted antimicrobial activity as natural antibiotics (Cultured Dairy Product J. 7-11). Binek M et al. Then demonstrated that lactic acid bacteria isolated from the digestive tract of chickens had antibacterial effects against Salmonella, Escherichia coli and Clostridium bacteria (Poultry J. Microbiol. 2005; 54 (4) 287-294). Belfiore et al. Reported that the growth of Escherichia coli was inhibited by bacteriocin, lactocin and nisin, which are antimicrobial peptides produced by lactic acid bacteria in the culture of lactic acid bacteria (Food microbiol, 2007 May; 24 (3)). 223-229), Stern NJ et al. Reported that bacteriocin, an antimicrobial peptide produced by Lactobacillus salivarius, significantly inhibited Clostridium bacteria (Antimicrob. Agents chemother., 2006 Sep; 50 (9) 3111-3116).

최근 항생·항균제의 오·남용에 따른 내성 문제 및 항생제의 배합사료첨가에 따른 축산물에 잔류문제가 전 세계적으로 문제화되면서 국가간의 통상마찰로까지 이어지고 있다. 2005년도 식품의약품안전청 자료에 따르면 식품과 축산물에 대장균 및 장구균의 80% 이상에서 항생제 내성이 발견되어 충격을 주고 있다. 이러한 축산물 및 식품의 항생·항균제의 잔류를 방지하기 위해서 미국 연방규정(Code of Federal Regulation)에서는 항생·항균제의 사료첨가규정(Food Additive Compendium)을 만들어 엄격하게 그의 사용을 제한하고 있으며, 유럽연합 역시 EEC규정(Annex I of council regulation)에 의하여 항생·항균제의 축종별 사용을 엄격하게 통제하고 있다. 우리나라에서도 약사법 제72조 및 동물용 의약품 등 취급규칙 제 46조의 규정에 의한 배합사료용 동물용 의약품사용기준에 따라 2005년 7월부터 사료첨가용 항생제의 사용을 53종에서 25종으로 많이 축소하여 항생물질의 사용을 규제하고 있다. 더불어 농림부에서는 축산물 위생 안정성 재고 종합대책 및 항생제 등 항균물질 사용절감 방안을 발표하여 항생제 대체물질인 생균제, 효소제, 유기산제, 약용식물 제제 및 천연성분의 생리활성 촉진제제 등의 개발 및 공급을 지원하고 있으며, 사용되고 있는 항생제 대체물질로서는 생균제가 대부분을 차지하고 있다. 그러나 생균제는 동물의 소화관이 시험관과 다르기 때문에 장관에 영구하게 정착하는 것을 나타내는 증거가 불분명하고 지속적인 효과가 필요하면 연속적으로 투여하여야 하는 문제점이 있다(Fuller, 1992, 축산의 연구 제46권 제1호, 44). Recently, the problem of resistance due to misuse and abuse of antibiotics and antimicrobial agents and the problem of residues in livestock products due to the addition of antibiotic feed have led to trade friction between countries. According to the 2005 Food and Drug Administration data, food and livestock products are shocking to find antibiotic resistance in more than 80% of E. coli and enterococci. In order to prevent antibiotic and antimicrobial residues in livestock and food products, the US Code of Federal Regulation has created a Food Additive Compendium for antibiotics and antimicrobials and strictly restricts their use. The Annex I of council regulation strictly controls the use of antibiotics and antibiotics by species. In Korea, in accordance with the criteria for the use of veterinary medicine for formulated feed under Article 72 of the Pharmaceutical Affairs Act and Article 46 of the Handling Rules of Animal Medicine, the use of feed additive antibiotics was reduced from 53 to 25 in July 2005. Regulates the use of materials. In addition, the Ministry of Agriculture and Forestry announced comprehensive measures for the hygiene and stability of livestock products and measures to reduce the use of antimicrobial substances, including antibiotics, to support the development and supply of antibiotic substitutes such as probiotics, enzymes, organic acids, medicinal plant preparations, and natural ingredients. Probiotics make up the bulk of antibiotics used. However, because probiotics differ from the test tubes of animals, there is a problem that the evidence indicating permanent settling in the intestine is unclear and should be continuously administered if a continuous effect is needed (Fuller, 1992, Livestock Research Vol. 46, No. 1). , 44).

또한, 주위 환경조건에 따라 기대하는 효과가 미흡하고 안정성(stability)에 문제가 있어 유통과정이나 사료의 가공처리 특히, 펠렛사료, 크럼블사료 및 후레이크사료 등 열처리 가공 사료의 경우 제조과정 중 70내지 120의 높은 고열과 스팀으로 말미암아 생균이 죽거나 활력이 저하되는 등 품질상에 문제점이 있다(이인호, Direct-fed microbials이론의 기술경영적 접근, 2000, 17-19). 대한민국 특허 제10-0261352(청정사료첨가제조성물 및 그 제조방법), 10-0396022호(가축용 생균제 및 가축용 생균제의 제조방법), 10-0489859호(가금티푸스치료 및 예방용 유산균 및 이를 이용하는 가금티푸스 치료방법), 10-0688441호(감귤박을 이용한 사료첨가제 및 그의 제조방법) 및 미국 특허 6,503,544호(Animal feed additive) 역시 모두 유산균을 이용한 동물용 사료첨가제에 관한 특허로서 근본적으로 안정성(stability)에 문제점을 갖고 있다. 생균제의 열에 대한 안정성(stability)문제를 해결하기 위하여 틴달화(tyldallization) 처리한 유산균제제가 개발되어 시판되고 있다. J.Fourniat등은 틴달화처리한 락토바실루스 아시도필루스(Lactobacillus acidophilus)를 대장균(E.coli)을 감염시킨 마우스(Swiss OF1)에 경구 투여한 결과 폐사율이 크게 감소함을 발견하였으며 이는 틴달화 열처리하는 과정에서 유산균이 생성하는 항균 펩타이드 물질이 크게 증가하는데 기인하는 것이라고 보고하였다(Microecology and therapy, Vol.14, 1984, 263-264). 현재 국내에서 시판되고 있는 틴달화 유산균제는 식품의약품안전청 의약품 등 기준 및 시험방법 제2개정에 락토바실루스 아시도필루스균 틴달화 동결건조물로서 등재되어 인체분야뿐만 아니라 축산분야에도 널리 사용되고 있으나 축산분야에 적용시 사용 비용이 비싸 경제동물인 닭, 돼지 및 소에 급여하기가 곤란하며, 항생제 대체제로서 항균효과가 미흡하다는 단점이 있다.In addition, depending on the environmental conditions, the expected effect is insufficient and there is a problem in stability (stability), so the processing process of the distribution process or feed, especially in the case of heat-treated feed such as pellet feed, crumble feed and flake feed during the manufacturing process The high heat and steam of 120 lead to the loss of viability and deterioration of vitality (Lee, In-Ho, Technology Management Approach to Direct-fed Microbials Theory, 2000, 17-19). Republic of Korea Patent No. 10-0261352 (Clean feed additive composition and its manufacturing method), 10-0396022 (Manufacturing method for livestock probiotics and livestock probiotics), 10-0489859 (Lactobacillus for treating and preventing poultry typhoid and poultry using the same Typhoid treatment method), 10-0688441 (feed additive using citrus gourd and its manufacturing method) and US Patent No. 6,503,544 (Animal feed additive) are all patents related to animal feed additives using lactic acid bacteria, and are fundamentally stable. I have a problem with In order to solve the problem of stability of heat of probiotics, a lactic acid bacterium that has been treated with tyldallization has been developed and marketed. J. Fourniat et al. Found that mortality was significantly reduced by oral administration of Lactobacillus acidophilus treated with E. coli (Swiss OF1). It was reported that the antimicrobial peptides produced by lactic acid bacteria were greatly increased during the heat treatment (Microecology and therapy, Vol. 14, 1984, 263-264). Currently, commercially available tindal lactobacillus is listed as the Lactobacillus asidophilus tindal freeze-dried product in the 2nd Amendment of Standards and Test Methods of the Korea Food and Drug Administration. It is difficult to feed chickens, pigs and cows, which are expensive to use when applied to economical animals, and there is a disadvantage that the antimicrobial effect is insufficient as an antibiotic substitute.

본 발명의 목적은 상기와 같은 문제점을 해결하기 위하여 통상의 유산균을 일정시간 배양 후 비테인(betaine)을 첨가하여 열처리하고 여기에 유카추출물(yucca extract)을 첨가하여 재 배양하는 과정을 2회 반복한 후 멸균처리하여 적당한 흡착제에 흡착시킨 다음 부형제에 혼합함으로써, 항균효과를 강화시킨 유산균제제 및 그 제조방법을 제공하는 데 있다.An object of the present invention is to repeat the process of culturing the conventional lactic acid bacteria in order to solve the above problems for a certain period of time after the heat treatment by the addition of betaine (betaine) and adding the yucca extract (yucca extract) twice After the sterilization process by adsorbing to a suitable adsorbent and then mixed with an excipient, to provide a lactic acid bacteria agent and a method for producing the enhanced antibacterial effect.

본 발명은 통상의 유산균을 34℃ 내지 37℃에서 일정시간 배양한 후 배양액 1중량부에 대하여 0.005 내지 0.2중량부의 비테인을 첨가하여 60℃내지 70℃에서 10분 내지 30분간 열처리 한 다음 34℃내지 37℃로 낮추고 배양액 1중량부에 대하여 0.001내지 0.05중량부의 유카추출물을 첨가하고 다시 23℃ 내지 37℃에서 일정시간 배양한 다음 배양액 1중량부에 대하여 0.005 내지 0.2중량부의 비테인을 다시 첨가하여 70℃ 내지 80℃에서 10분 내지 30분간 열처리한 다음 34℃ 내지 37℃로 낮추고 다시 배양액 1중량부에 대하여 0.001 내지 0.05중량부의 유카추출물을 첨가하고 34℃ 내지 37℃에서 일정시간 배양한 다음 121℃에서 15분 내지 30분간 멸균처리한 사균화 유산균 배양액 1중량부에 대하여 흡착제 4 내지 9중량부에 흡착한 후 사균화 유산균 배양액 흡착물 1중량부에 대하여 통상의 부형제 4 내지 19중량부에 혼합한 항균효과가 강화된 사료첨가용 유산균제제 조성물 및 그 제조방법에 관한 것이다. The present invention is incubated for a predetermined time at 34 ℃ to 37 ℃ conventional lactic acid bacteria and then 0.005 to 0.2 parts by weight of betaine is added to 1 part by weight of the culture and heat treatment at 60 ℃ to 70 ℃ 10 minutes to 30 minutes and then 34 ℃ To 0.001 to 0.05 parts by weight of yucca extract per 1 part by weight of the culture medium and incubated at 23 ° C. to 37 ° C. for a certain time, and then 0.005 to 0.2 parts by weight of betaine was added again to 1 part by weight of the culture solution. Heat-treated at 70 to 80 ℃ for 10 to 30 minutes, then lowered to 34 ℃ to 37 ℃, and then added 0.001 to 0.05 parts by weight of yucca extract per 1 part by weight of the culture medium and incubated for a certain time at 34 ℃ to 37 ℃ 121 1 to 4 parts by weight of the adsorbent to 1 part by weight of the sterilized lactic acid bacteria culture medium sterilized at 15 ° C. for 30 minutes, and then to 1 part by weight of the sterilized lactic acid bacteria culture medium adsorbate. Conventional excipients 4 to 19 parts by weight of lactic acid bacteria for the antibacterial effect is enhanced by the addition to the feed mixture preparation composition and to a method of manufacturing the same.

상기한 바와 같이, 유산균을 일정시간 배양 후 비테인을 첨가하여 열처리하고 유카추출물을 첨가하여 재 배양하는 과정을 2회 반복한 다음, 사균화 처리하고 흡착제 및 부형제에 흡착, 혼합하여 사료첨가용 유산균제제를 제조함으로서, 항균효과의 증강과 함께 열에 대한 안정성(stability)문제를 달성할 수 있다.As described above, the lactic acid bacteria were incubated for a predetermined time, followed by heat treatment with the addition of betaine, followed by re-cultivation with the addition of the yucca extract, followed by sterile treatment, adsorption and mixing with the adsorbent and the excipient to feed the lactic acid bacteria. By preparing the formulation, it is possible to achieve stability problems against heat with enhancement of the antimicrobial effect.

이하 본 발명을 상세하게 설명한다.Hereinafter, the present invention will be described in detail.

본 발명은 크게 (a)유산균 배양 및 열처리단계와 (b)상기 열처리가 완료된 유산균 배양액의 흡착 및 혼합 단계로 구성된다. The present invention is largely composed of (a) lactic acid bacteria culture and heat treatment step and (b) the adsorption and mixing step of the lactic acid bacteria culture solution is completed the heat treatment.

상기 단계 (a)의 유산균 배양 및 열처리 단계는 3단계로 나누어 실시될 수 있는바,Lactic acid bacteria culture and heat treatment step of step (a) can be carried out divided into three steps,

첫 번째 단계로서는 통상의 유산균(미국 National Feed Ingredients Association에서 승인된 Lactobacillus acidophilus, L.brevis, L.casei, L.fermentum, L.lactis, L.plantarum, L.bulgaricus, L.reuteri 등)을 유산균 배양배지를 사용하여 34℃내지 37℃하에서 6 내지 12시간 배양한 후 비테인(betaine)을 첨가한 다음 60℃내지 70℃에서 10 내지 30분간 열처리한다. As a first step, conventional lactic acid bacteria (Lactobacillus acidophilus, L.brevis, L.casei, L.fermentum, L.lactis, L.plantarum, L.bulgaricus, L.reuteri, etc.) approved by the US National Feed Ingredients Association After 6 to 12 hours of incubation at 34 ° C. to 37 ° C. using a culture medium, betaine was added thereto, followed by heat treatment at 60 ° C. to 70 ° C. for 10 to 30 minutes.

이때, 본 발명에 사용되는 비테인은 사탕무 또는 사탕수수에서 추출되는 알칼로이드의 일종이며 삼투물질(osmolyte)로서 열처리시 유산균을 보호하고 추후 배양시 유산균의 활력을 활성화해주는 작용을 한다. 따라서 열처리시 비테인을 일정량 첨가함으로써 유산균에 의한 항균 펩타이드 물질 생산량이 증가되어 항균효과가 증진되는 것으로 추측되고 있다. 상기 비테인의 첨가량은 배양액 1중량부에 대하여 0.005 내지 0.2중량부 정도인 것이 바람직한데, 0.005중량부 미만인 경우에는 열처리시 유산균의 삼투압 보호제로서의 효과를 충분히 발휘할 수 없으며 0.2중량부를 초과하는 경우에는 지나친 과량사용으로 바람직하지 못하다. At this time, betaine used in the present invention is a kind of alkaloids extracted from sugar beet or sugar cane, and acts as an osmolyte to protect the lactic acid bacteria during heat treatment and activate the vitality of the lactic acid bacteria in the subsequent culture. Therefore, by adding a certain amount of betaine during heat treatment, it is estimated that the antimicrobial effect of the antimicrobial peptide material is increased by lactic acid bacteria, thereby enhancing the antimicrobial effect. The amount of the bitine added is preferably about 0.005 to 0.2 parts by weight with respect to 1 part by weight of the culture medium, when less than 0.005 parts by weight can not fully exert the effect of the lactic acid bacteria as an osmotic pressure protection agent during heat treatment, if exceeding 0.2 parts by weight Overuse is undesirable.

그리고 두 번째 단계로 상기 첫째 단계와 같이 열처리가 완료된 배양액에 유카추출물 적당량을 첨가하여 34℃ 내지 37℃하에서 다시 6 내지 12시간 배양한 후 또다시 비테인을 첨가하고 이번에는 70℃ 내지 80℃에서 10 내지 30분간 열처리한다. 본 발명에서 사용되는 유카추출물(yucca extract)은 아메리카 대륙에서 주로 서식하는 유카 시디게라(Yucca schidigera)라는 식물에서 추출한 천연물질로서 사르사포닌(sarsaponin)이 5%이상 함유되어 있어야 한다. 유카추출물은 축산분야에서 축사의 악취제거, 가축의 성장촉진, 육질개선 및 사료효율개선 목적으로 사용되고 있으며, 본 발명에서는 열처리시 균체들의 응집을 방지하고 생존한 유산균의 증식을 촉진하기 위하여 사용하였다. 상기 유카추출물의 첨가량은 배양액 1중량부에 대하여 0.01 내지 0.05중량부 정도인 것이 바람직한데, 0.001중량부 미만 시는 유산균체의 응집 방지효과가 미흡하고 0.05 중량부를 초과하는 경우에는 지나친 과량사용으로 바람직하지 못하다. 비테인의 첨가량은 첫 번째 단계와 같이 배양액 1중량부에 대하여 0.005 내지 0.2중량부가 바람직하다.  In the second step, the appropriate amount of yucca extract was added to the culture solution, which was heat-treated as in the first step, incubated again for 6 to 12 hours at 34 ° C. to 37 ° C., and then, again, betaine was added, and this time at 70 ° C. to 80 ° C. Heat-treat for 10-30 minutes. Yucca extract (yucca extract) used in the present invention is a natural substance extracted from a plant called Yucca schidigera, which mainly lives in the Americas, and should contain at least 5% of sarsaponin. Yucca extract is used for animal odor removal, animal growth promotion, meat quality improvement and feed efficiency improvement in the livestock field, and in the present invention, it was used to prevent the aggregation of cells during heat treatment and to promote the growth of surviving lactic acid bacteria. The addition amount of the yucca extract is preferably about 0.01 to 0.05 parts by weight based on 1 part by weight of the culture medium, when less than 0.001 parts by weight is insufficient to prevent the aggregation of lactic acid bacteria, and when the excess exceeds 0.05 parts by weight is preferable to use excessively. I can't. The amount of bitine added is preferably 0.005 to 0.2 parts by weight based on 1 part by weight of the culture as in the first step.

세 번째 단계로서는 상기 두 번째 단계와 같이 2차 열처리가 완료된 배양액에 다시 유카추출물을 적당량 첨가하여 34℃ 내지 37℃하에서 6 내지 12시간 배양한 다음 121℃에서 15분 내지 30분간 멸균처리하여 (a)단계의 최종 산물인 사균화 유산균 배양액을 제조한다. 상기 유카추출물의 첨가량은 항에서와 같이 배양액 1중량부에 대하여 0.001 내지 0.05 중량부가 바람직하다. As a third step, add the appropriate amount of Yucca extract to the culture solution after the second heat treatment as in the second step, incubated for 6 to 12 hours at 34 ℃ to 37 ℃ and sterilized for 15 minutes to 30 minutes at 121 ℃ (a Prepare the sterile lactic acid bacteria culture medium, which is the final product of step). The amount of the yucca extract is preferably 0.001 to 0.05 parts by weight based on 1 part by weight of the culture as described in the paragraph.

상기 단계 (b)흡착 및 혼합단계는 두 가지의 단계로 나누어 실시될 수 있는바,The step (b) adsorption and mixing can be carried out divided into two stages,

그 첫 번째 단계로서는 (a)단계 세 번째 단계에서 얻어진 사균화 유산균 배양액을 통상의 흡착제(예를 들면 제올라이트, 이산화규소, 메틸셀룰로오스 등)에 살포하면서 흡착시킨다. 상기 흡착제의 첨가량은 사균화 유산균 배양액 1 중량부에 대하여 4 내지 9 중량부 정도인 것이 바람직한데, 4중량부 미만인 경우 수분함량이 높아 보존성에 문제점이 있으며 9 중량부를 초과하는 경우에는 흡착제의 소요량이 많아 바람직하지 못하다. As the first step, the bactericidal lactic acid culture medium obtained in the third step (a) is adsorbed while being sprayed onto a common adsorbent (for example, zeolite, silicon dioxide, methyl cellulose, etc.). The amount of the adsorbent is preferably about 4 to 9 parts by weight based on 1 part by weight of the bactericidal lactic acid bacteria culture medium. When the amount of the adsorbent is less than 4 parts by weight, the moisture content is high, and when the amount of the adsorbent exceeds 9 parts by weight, the amount of the adsorbent is required. Many are not desirable.

두 번째 단계로서는 상기 첫 번째 단계에서 얻어진 사균화 유산균 배양액 흡착물과 통상의 부형제(예를 들면 왕겨분, 말분, 전분, 유당 등)를 혼합기에 넣고 10 내지 20분동안 35RPM 속도로 교반하여 최종적으로 항균효과가 강화된 사료첨가용 유산균제제를 제조할 수 있다. 상기 부형제의 첨가량은 사균화 유산균 배양액 흡착물 1중량부에 대하여 4 내지 19중량부 정도인 것이 바람직한데, 4중량부 미만인 경우는 사료에 첨가시 사용량이 적어 혼합도에 문제가 발생될 수 있으며 19중량부를 초과하는 경우에는 사료에 첨가시 사용량이 많아 혼합시 불편함을 초래할 수 있어 바람직하지 못하다. In the second step, the adsorbed sterilized lactic acid culture medium obtained in the first step and the usual excipients (e.g. chaff powder, powder, starch, lactose, etc.) were added to the mixer and stirred at 35 RPM for 10 to 20 minutes. Lactobacillus preparations can be prepared for enhanced antimicrobial effect. The amount of the excipient added is preferably about 4 to 19 parts by weight based on 1 part by weight of the bactericidal lactic acid bacteria adsorbate. When the amount of the excipient is less than 4 parts by weight, the amount of the excipient added to the feed may cause problems in mixing. If it exceeds the weight part, it is not preferable because the amount used when added to the feed may cause inconvenience when mixing.

이하, 본 발명을 실시 예 및 비교 예에 의거하여 더욱 상세하게 설명하겠는바, 본 발명이 이에 한정되는 것은 아니다Hereinafter, the present invention will be described in more detail based on Examples and Comparative Examples, but the present invention is not limited thereto.

[실시 예 및 비교 예][Examples and Comparative Examples]

<실시 예 1><Example 1>

락토바실루스 아시도필루스(Lactobacillus acidophilus KCTC 3164) 스타터를 MRS 배지에 2%(v/v) 무균적으로 접종한 후 37에서 8시간 배양한 후 멸균 처리한 비테인을 배양액 1중량부에 대하여 0.01중량부 첨가한 후 65℃에서 10분간 1차 열처리하고 37℃로 낮춘 다음, 배양액 1중량부에 대하여 0.01중량부의 멸균 처리한 유카추출물을 첨가하여 37℃에서 8시간 배양한 후 재차 멸균 처리환 비테인을 배양액 1중량부에 대하여 0.01중량부 첨가한 다음 75℃에서 20분간 2차 열처리를 하였다. 다음, 배양액 1중량부에 대하여 0.01중량부의 멸균 처리한 유카추출물을 다시 첨가하여 37℃에서 8시간 배양한 후 121℃에서 15분간 멸균 처리하여 사균화 유산균 배양액을 제조하였다.After aseptically inoculating 2% (v / v) of Lactobacillus acidophilus KCTC 3164 starter in MRS medium and incubating for 8 hours at 37, sterilized bitine was added to 0.01 part by weight of the culture medium. After adding the parts by weight, the first heat treatment at 65 ℃ for 10 minutes and lowered to 37 ℃, and then added 0.01 parts by weight of sterilized yucca extract to 1 part by weight of the culture and incubated for 8 hours at 37 ℃ and then again sterilized Phosphorus was added 0.01 part by weight based on 1 part by weight of the culture solution, followed by secondary heat treatment at 75 ° C. for 20 minutes. Next, 0.01 parts by weight of sterilized yucca extract was added to 1 part by weight of the culture medium, followed by incubation at 37 ° C. for 8 hours, and sterilization at 121 ° C. for 15 minutes to prepare a bactericidal lactic acid bacteria culture medium.

<실시 예 1-1><Example 1-1>

상기 <실시 예 1>에서 제조된 사균화 유산균배양액 1중량부에 대하여 7중량부의 제올라이트를 혼합기에 넣고 30RPM속도로 교반하면서 사균화 유산균 배양액을 분사하여 사균화 유산균 배양액 흡착물을 제조한 다음, 사균화 유산균 배양액 흡착물 1중량부에 대하여 12중량부의 왕겨분을 혼합기내에 추가하여 35RPM속도로 15분간 혼합하여 사료첨가용 유산균제제를 제조하였다.7 parts by weight of zeolite was added to 1 part by weight of the bactericidal lactic acid bacteria culture medium prepared in <Example 1>, and the bactericidal lactic acid culture medium adsorbed was prepared by spraying the bactericidal lactic acid culture medium while stirring at 30 RPM. 12 parts by weight of rice hull powder was added into the mixer with respect to 1 part by weight of the lactic acid bacteria culture medium adsorbate, and mixed for 15 minutes at a speed of 35 RPM to prepare a lactic acid bacteria preparation for feed addition.

<비교 예 1><Comparative Example 1>

락토바실루스 아시도필루스(Lactobacillus acidophilus KCTC 3164) 스타터를 MRS배지에 2%(v/v)무균적으로 접종한 후 37℃에서 8시간 배양한 후 65℃에서 10분 간 1차로 열처리를 하였다. 다음, 상기 배양액을 37℃에서 8시간 배양한 후 이번에는 75℃에서 20분간 2차 열처리를 하였다. 다음, 상기 배양액을 37℃에서 8시간 배양한 후 121℃에서 15분간 멸균 처리하여 사균화 유산균 배양액을 제조하였다.Lactobacillus acidophilus KCTC 3164 starter was inoculated 2% (v / v) aseptically into MRS medium and incubated at 37 ° C for 8 hours, followed by primary heat treatment at 65 ° C for 10 minutes. Next, the culture solution was incubated at 37 ° C. for 8 hours and then subjected to secondary heat treatment at 75 ° C. for 20 minutes. Next, the culture was incubated for 8 hours at 37 ℃ sterilized for 15 minutes at 121 ℃ to prepare a bactericidal lactic acid bacteria culture.

<비교 예 1-1><Comparative Example 1-1>

상기 <비교예 1>에서 제조된 사균화 유산균 배양액을 <실시예 1-1>과 동일한 방법으로 하여 사료첨가용 유산균제제를 제조하였다.Lactobacillus lactic acid bacteria culture solution prepared in <Comparative Example 1> was prepared in the same manner as in <Example 1-1> to prepare a lactic acid bacteria preparation for feed addition.

<비교 예 2><Comparative Example 2>

락토바실루스 아시도필루스(Lactobacillus acidophilus KCTC 3164) 스타터를 MRS배지에 2%(v/v) 무균적으로 접종한 후 37℃에서 24시간 배양하여 사균화 처리하지 않은 유산균배양액을 제조하였다.Lactobacillus acidophilus KCTC 3164 starter was inoculated 2% (v / v) aseptically into the MRS medium and then cultured at 37 ℃ for 24 hours to prepare a lactic acid bacteria culture solution without the bactericidal treatment.

<비교 예 2-1><Comparative Example 2-1>

상기 <비교 예 2>에서 제조된 사균화 처리하지 않은 유산균배양액을 <실시 예 1-1>과 동일한 방법으로 하여 사료첨가용 유산균제제를 제조하였다.The lactic acid bacteria culture solution that had not been sterilized in <Comparative Example 2> was prepared in the same manner as in <Example 1-1> to prepare a lactic acid bacteria preparation for feed addition.

<실험 예 1>Experimental Example 1

유산균 배양액의 항균효과 비교Comparison of Antimicrobial Effects of Lactic Acid Bacteria Cultures

1. 시험방법1. Test Method

본 발명의 실시 예 1과 비교 예 1 및 비교 예 2에서 제조된 각각의 유산균배양액에 대한 항균력을 측정, 비교평가하기 위하여 원판확산법(Kirby-Bauer disk diffusion method)을 사용하였다. 시험균주로는 대장균(E.coli)과 살모넬라갈리나룸(Salmonella gallinarum)을 사용하였다. 배양한 시험균액을 희석하여 균의 농도 가 1×108CFU/ml가 되도록 조절하여 평판 한천배지 위에 각 각 100-150㎕를 떨어뜨려 멸균 삼각 스프레더(spreader)로 골고루 도말한 후 평판 뚜껑을 닫고 3-5분 동안 방치하여 표면의 습기가 흡수되도록 한 다음 15분 이내에 배지 위에 지름 6.35mm 두께 1.5mm 시험원판(paper disk)을 올려놓고 실시 예1, 비교 예1 및 비교 예2 각각의 유산균배양액을 각 각의 원판 위에 50씩 접종하여 30분 동안 정치시킨 후 37℃ 배양기에 평판 뚜껑이 밑으로 가도록 놓아 18시간 배양 후 원판 주위의 세균 증식억제대의 지름을 자를 이용하여 측정하였다.Kirby-Bauer disk diffusion method was used to measure and compare the antimicrobial activity of each lactic acid bacteria culture medium prepared in Example 1, Comparative Example 1 and Comparative Example 2 of the present invention. E. coli and Salmonella gallinarum were used as test strains. Dilute the cultured test solution so that the concentration of bacteria is 1 × 10 8 CFU / ml, drop 100-150 μl onto each plate agar, and spread it evenly with a sterile triangular spreader. Leave for 3-5 minutes to allow the surface to absorb moisture, and within 15 minutes, put a 6.35mm diameter 1.5mm paper disk on the medium, and then culture the lactic acid bacteria in each of Examples 1, 1 and 2. Was inoculated 50 times on each original plate and left for 30 minutes, and the plate lid was placed in the incubator at 37 ° C. under the culture for 18 hours, and the diameter of the bacterial growth inhibitor around the plate was measured using a ruler.

2. 시험결과2. Test result

실시 예1, 비교 예1 및 비교 예2 모두 시험균주인 대장균과 살모넬라균에 대하여 항균활성을 나타내었다. 그러나 비교 예 1 이 비교 예 2에 비하여 항균활성이 우수하였으며, 실시 예 1이 비교 예 1에 비하여 항균활성이 우수하여 항균효과가 가장 탁월하였다. 실험결과는 표 1과 같다.Example 1, Comparative Example 1 and Comparative Example 2 all showed antimicrobial activity against test strains E. coli and Salmonella. However, Comparative Example 1 was excellent in antimicrobial activity compared to Comparative Example 2, Example 1 was excellent in antimicrobial activity compared to Comparative Example 1, the antibacterial effect was the most excellent. The experimental results are shown in Table 1.

항균활성화의 크기(단위:nm)Size of Antimicrobial Activation (Unit: nm) 대장균Escherichia coli 살모넬라 갈리나룸Salmonella Galinarum 실시예 1Example 1 11.111.1 10.310.3 비교예 1Comparative Example 1 10.410.4 9.59.5 비교예 3Comparative Example 3 9.89.8 8.38.3

<실험 예 2>Experimental Example 2

닭에 대한 사료첨가용 유산균제제의 질병예방 효과Disease Prevention Effect of Lactic Acid Bacteria for Feed Additives in Chickens

1. 실험방법1. Experimental method

5일령 육용병아리(Cobb) 96마리를 24마리씩 4개 군으로 나누어 육계전기사료에 대조군은 무첨가, 시험1군은 실시 예 1-1에서 제조된 사료첨가용 유산균제제를 0.2% 첨가, 시험2군은 비 교예 1-1에서 제조된 사료첨가용 유산균제제를 0.2% 첨가, 시험3군은 비교 예 2-1에서 제조된 사료첨가용 유산균제제를 0.2% 각 각 첨가하여 25일령까지 급여하였다. 각각의 사료첨가용 유산균제제의 살모넬라균에 대한 질병 예방효과를 측정하기 위하여 15일령의 모든 병아리에 마리당 108CFU씩 살모넬라 갈리나룸균을 구강으로 인공 감염시킨 후 시험 종료시(25일령)까지 폐사 마릿수 측정하였다.Five-day-old broiler chickens (Cobbs) were divided into four groups of 24 each of 24 animals, and the control group was not added to broiler electric feed, and the test group 1 added 0.2% of the lactic acid bactericide for feed addition prepared in Example 1-1 0.2% of the feed additive lactic acid bacteria prepared in Comparative Example 1-1 was added, and test 3 group was fed up to 25 days of age by adding 0.2% of the lactic acid bacteria for feed additive prepared in Comparative Example 2-1. In order to measure the disease prevention effect of each feed supplement lactobacillus against Salmonella, the number of mortality was measured until the end of the test (25 days old) after artificially infecting Salmonella gallinarum bacteria by 10 8 CFU per horse to all chicks at 15 days of age. It was.

2. 시험결과2. Test result

사료첨가용 유산균제제를 투여하지 않은 대조군에서는 총 10마리가 폐사하여 41.7%의 폐사율을 보였으며, 사균화 처리하지 않은 사료첨가용 유산균제제인 비교 예 2-1을 사료에 첨가하여 급여한 시험3군은 총 5마리가 폐사하여 20.8%의 폐사율을 보였다. 반면, 사균화 처리한 사료첨가용 유산균제제인 비교 예 1-1을 사료에 첨가하여 급여한 시험2군은 총 4마리가 폐사하여 16.7%의 폐사율을 보였으며 사균화 처리한 사료첨가용 유산균제제 실시 예 1-1을 사료에 첨가하여 급여한 시험1군의 총 폐사 마리 수는 3마리로서 12.5%의 폐사율을 보였다. 따라서 비테인과 유카추출물을 첨가하여 사균화 처리한 사료첨가용 유산균제제(실시 예 1-1)를 급여한 계군의 폐사율이 사균화 처리하지 않은 일반 사료첨가용 유산균제제(비교 예 2-1)를 급여한 계군에 비해 폐사율이 8.3% 낮았으며, 사균화 처리한 사료첨가용 유산균제제(비교 예 1-1)를 급여한 계군에 비해서는 폐사율이 4.2% 낮았다. 실험결과는 [표 2]와 같다.In the control group that did not receive the feed supplement lactobacillus, a total of 10 animals died and showed a mortality rate of 41.7%. A total of 5 animals died in the group, resulting in 20.8% mortality. On the other hand, in Test 2 group, which was fed and fed Lactobacillus lactic acid bactericide, which had been added to the feed, was fed 4 rats, resulting in 16.7% mortality. The total number of mortality in test 1 group fed Example 1-1 to feed was 3, showing 12.5% mortality. Therefore, lactobacillus for general feed supplementation without mortality of feed group lactobacillus supplemented with bactericidal treatment by adding betaine and yucca extract (Example 1-1) (Comparative Example 2-1) The mortality rate was 8.3% lower than that of the broilers fed the diet, and the mortality was 4.2% lower than those fed the lactobacillus supplements treated with sterile feed (Comparative Example 1-1). The experimental results are shown in [Table 2].

시험 마리수The number of trials 폐사 마리수Our number 폐사율Mortality 대조군Control 2424 1010 41.7%41.7% 시험1군Test group 1 2424 33 12.5% 12.5% 시험2군Test 2 group 2424 44 16.7%16.7% 시험3군Test Group 3 2424 55 20.8%20.8%

<실험 예 3>Experimental Example 3

돼지에 대한 사료첨가용 유산균제제의 질병 예방효과Disease Prevention Effect of Lactic Acid Bacteria for Feed Additives in Pigs

1. 실험방법1. Experimental method

이유 후부터 다양한 바이러스와 세균에 의한 소화기 질병과 호흡기질병 등과 관련이 있는 것으로 알려진 PMWS(postweaning multisystenic wasting syndrome)로 생산성이 떨어져 있는 경기도 소재 A양돈장의 이유자돈(Landrace×Yorkshire×Duroc) 180두를 무작위로 착출하여 45마리씩 4개군으로 나누어 자돈사료에 대조군은 무첨가, 시험1군은 실시 예 1-1에서 제조된 사료첨가용 유산균제제를 0.2%, 시험2군은 비교예 1-1에서 제조된 사료첨가용 유산균제제를 0.2%, 시험3군은 비교 예 2-1에서 제조된 사료첨가용 유산균제제를 0.2%씩 각각 첨가하여 68일령까지 급여하였다. 시험 전 기간 자돈의 체중변화, 사료섭취량, 사료요구율, 위축과 폐사 두수를 측정하였으며, 폐사원인은 부검을 하여 병변이 있는 조직을 미생물학적 및 병리학적 검사를 하여 규명하였다. 임상증상지수는 0: 정상, 1: 가벼운 정도에서 중등도의 의기소침, 2: 심한 정도의 의기소침, 운동거부, 신경증상 및 위축, 20: 폐사를 매일 일정한 시간에 관찰하여 임상증상 점수×관찰된 두수=임상증상 누적지수로 표시하였다. 시험 전 기간 동안 모든 자돈은 시험양돈장의 동일한 사육환경과 사양관리 하에서 실시하였으며, 사료 급여는 농장사양프로그램에 준하였고, 음수는 자유 급여토록 하였다. After weaning, we randomly harvest 180 heads of weaned pigs (Landrace × Yorkshire × Duroc) of A pig farm in Gyeonggi-do, which is known to be associated with various viral and bacterial digestive diseases and respiratory diseases. The control group was added to the piglet feed, divided into four groups of 45 animals each, and the test group 1 was 0.2% of the lactic acid bacteria preparation for feed addition prepared in Example 1-1, and the test group 2 was added to the feed prepared in Comparative Example 1-1. Lactobacillus agent 0.2%, test 3 groups were fed up to 68 days of age by adding 0.2% each of the lactic acid bacteria agent for feed additive prepared in Comparative Example 2-1. The weight change, feed intake, feed demand, atrophy and mortality of piglets were measured during the entire test period. The cause of mortality was necropsy and the tissues with lesions were identified by microbiological and pathological examination. The clinical symptom index was 0: normal, 1: mild to moderate depression, 2: severe depression, refusal to exercise, neurological symptoms and atrophy; 20: mortality was observed at regular times daily for clinical symptoms score × Number of heads = clinical symptom cumulative index. All piglets were tested under the same breeding conditions and control of the pig farm during the pre-test period. Feeding was in accordance with the farm feeding program and negative drinking was allowed.

2.시험결과2. Test Results

1)사료효율 개선효과1) Feed efficiency improvement effect

시험기간 동안(21일령부터 68일령까지) 두당 평균 증체량은 사료첨가용 유산균제제를 첨가하지 않은 사료를 급여한 대조군이 17.9kg, 사균화 처리하지 않은 사료첨가용 유산균제제(비교 예 2-1)를 사료에 첨가하여 급여한 시험3군은 19.3kg, 사균화 처리한 사료첨가용 유산균제제(비교 예 1-1)를 사료에 첨가하여 급여한 시험2군은 19.6kg, 사균화 처리한 사료첨가용 유산균제제(실시 예 1-1)를 사료에 첨가하여 급여한 시험1군은 20.3kg이었다. 반면, 시험기간 동안(21일령부터 68일령 까지) 두당 평균 사료섭취량은 사료첨가용 유산균제제를 첨가하지 않은 사료를 급여한 대조군이 39.9kg, 사균화 처리하지 않은 사료첨가용 유산균제제(비교 예 2-1)를 사료에 첨가하여 급여한 시험3군은 40.7kg, 사균화 처리한 사료첨가용 유산균제제(비교예 1-1)를 사료에 첨가하여 급여한 시험2군은 40.6kg, 사균화 처리한 사료첨가용 유산균제제(실시 예 1-1)를 사료에 첨가하여 급여한 시험1군은 40.2kg으로 사료요구율(사료섭취량/증체량)을 환산시 대조군이 2.23, 시험3군이 2.11, 시험2군이 2.07, 시험1군이 1.98로서 사료첨가용 유산균제제를 급여한 돈군이 전체적으로 대조군에 비하여 향상되었으며 실시 예1-1 사료첨가용 유산균제제를 급여한 시험1군의 개선율이 가장 우수하였다.The mean weight gain per head during the trial period (from 21 to 68 days of age) was 17.9 kg from the control group fed the feed without the addition of lactobacillus supplements, and the lactobacillus supplements without the sterilization treatment (Comparative Example 2-1). Test 3 group fed with feed to feed was 19.3kg, Lactobacillus feed supplemented with sterilized feed (Comparative Example 1-1) was added to feed and tested 2 group fed 19.6kg, Feed added with sterilized feed The test 1 group fed with a lactic acid bacteria preparation (Example 1-1) to feed was 20.3 kg. On the other hand, the average feed intake per head during the test period (from 21 to 68 days of age) was 39.9 kg in the control group fed the feed without the addition of the lactic acid bacterium for the feed, and the lactic acid bacterium for the feed addition without the sterilization treatment (Comparative Example 2 Test 3 group fed with -1) to feed was 40.7kg, and test 2 group fed and supplemented with lactic acid bactericide for feed sterilization (Comparative Example 1-1) was 40.6kg and sterilized. The test 1 group fed with a feed supplemented lactic acid bacterium (Example 1-1) to the feed was 40.2 kg, and the control group was 2.23, the test group 3 was 2.11, the test 2 Group 2.07, Test 1 group 1.98, pig group fed feed lactic acid bacteria was improved as compared to the control group as a whole Example 1-1 Test 1 group fed the lactic acid bacteria for feed additives improved the most.

실험결과는 [표 3]과 같다. The experimental results are shown in [Table 3].

대조군Control 시험1군Test group 1 시험2군Test 2 group 시험3군Test Group 3 시험두수(두)Test head (two) 4545 4545 4545 4545 평균두당개시체중(kg)Starting weight per head (kg) 5.85.8 5.75.7 5.75.7 5.95.9 평균두당종료체중(kg)Average head weight per head (kg) 23.723.7 26.026.0 25.325.3 25.225.2 평균두당증체량(kg)Average head glucose gain (kg) 17.917.9 20.320.3 19.619.6 19.319.3 두당사료섭취량(kg)Soy sugar intake (kg) 39.939.9 40.240.2 40.640.6 40.740.7 사료요구율(FCR)Feed demand rate (FCR) 2.232.23 1.981.98 2.072.07 2.112.11 대조군대비 개선률(%)% Improvement over control 11.211.2 7.27.2 5.45.4

2)임상증상지수 및 폐사율 감소효과2) Clinical symptoms index and mortality reduction effect

각 군별 임상증상 누적지수는 사료첨가용 유산균제제를 첨가하지 않은 사료를 급여한 대조군이 202, 사균화 처리하지 않은 사료첨가용 유산균제제(비교예 2-1)를 사료에 첨가하여 급여한 시험3군이 139, 사균화 처리한 사료첨가용 유산균제제(비교예 1-1)를 사료에 첨가하여 급여한 시험2군이 117, 사균화 처리한 사료첨가용 유산균제제(실시예 1-1)를 사료에 첨가하여 급여한 시험1군이 62이었다. 각 군별 폐사율은 사료첨가용 유산균제제를 첨가하지 않은 사료를 급여한 대조군이 16.7%, 사균화 처리하지 않은 사료첨가용 유산균제제(비교예 2-1)를 사료에 첨가하여 급여한 시험3군은 11.1%, 사균화 처리한 사료첨가용 유산균제제(비교예 1-1)를 사료에 첨가하여 급여한 시험2군은 8.9%, 사균화 처리한 사료첨가용 유산균제제(실시예 1-1)를 사료에 첨가하여 급여한 시험1군은 4.4%이었다. 전반적으로 실험군들이 대조군에 비하여 PMWS에 의한 임상증상 누적지수 및 폐사율에서 낮게 관찰되었다. 결과는 [표 4]와 같다.The cumulative index of clinical symptoms for each group was 202, the control group fed the feed without the addition of lactic acid bacteria for feed, and the feed supplemented with the addition of the lactic acid bacteria for feed addition (Comparative Example 2-1). Group 139, Lactobacillus for Feed Addition (Comparative Example 1-1), added to the feed and fed to Group 2, Group 117, Lactobacillus for Feed Additive Treated (Example 1-1) The test 1 group fed to the diet was 62. The mortality rate of each group was 16.7% in the control group fed the feed without the addition of lactic acid bacteria for feed, and the test 3 group supplemented with the addition of the lactic acid bacteria for the feed without the sterilization (Comparative Example 2-1). 11.1%, Lactobacillus for feed supplementation (Comparative Example 1-1) supplemented with feed was added to the feed, and Test 2 group fed 8.9%, Lactobacillus for feed supplementation (Example 1-1). In the test group, 4.4% were added to the diet. Overall, the experimental group showed lower clinical cumulative index and mortality rate by PMWS than the control group. The results are shown in [Table 4].

시험 두수Test head 임상증상 누적지수*Cumulative Index of Clinical Symptoms * 폐사 두수Our head 폐사율 (%)Mortality (%) 폐사 원인Cause of death 병원체Pathogen 00 1One 22 33 2020 system 대조군Control 4545 00 1111 1616 1515 160160 202202 88 16.716.7 PMWS Glasser's diseasePMWS Glasser's disease PCV-2, PRRSV, H. parasuis , Sal . typhimurium B. dysenteria M. hyopneumoniae P. multocida PCV-2, PRRSV, H. parasuis , Sal . typhimurium B. dysenteria M. hyopneumoniae P. multocida 시험1군Test group 1 4545 00 66 1010 66 4040 6262 22 4.44.4 PMWSPMWS PCV-2, PRRSV, H. parasuis , M. hyopneumoniae P. multocida PCV-2, PRRSV, H. parasuis , M. hyopneumoniae P. multocida 시험2군Test 2 group 4545 00 77 1818 1212 8080 117117 44 8.98.9 PMWSPMWS PCV-2, PRRSV, H. parasuis , M. hyopneumoniae P. multocida PCV-2, PRRSV, H. parasuis , M. hyopneumoniae P. multocida 시험3군Test Group 3 4545 00 1010 1111 1818 100100 139139 55 11.111.1 PMWSPMWS PCV-2, PRRSV, H. parasuis , M. hyopneumoniae P. multocida PCV-2, PRRSV, H. parasuis , M. hyopneumoniae P. multocida

*: 임상증상을 보인 두수 ×임상증상지수,*: Two heads with clinical symptoms × clinical symptoms index,

**: 0; 정상, 1; 식욕부진, 2; 가벼운 정도에서 중등도의 의기소침, **: 0; Normal, 1; Anorexia, 2; Moderate to moderate depression,

3; 심한 정도의 의기소침, 운동거부, 신경증상 및 위축, 20; 폐사.    3; Severe depression, motor refusal, neurological symptoms and atrophy, 20; Our company.

상기한 바와 같이, 유산균을 일정시간 배양 후 비테인을 첨가하여 열처리하고 유카추출물을 첨가하여 재 배양하는 과정을 2회 반복한 다음, 사균화 처리하고 흡착제 및 부형제에 흡착, 혼합하여 사료첨가용 유산균제제를 제조함으로서 항균효과가 증강되고 열에 대한 안정성(stability)문제를 극복할 수 있다.As described above, the lactic acid bacteria were incubated for a predetermined time, followed by heat treatment with the addition of betaine, followed by re-cultivation with the addition of the yucca extract, followed by sterile treatment, adsorption and mixing with the adsorbent and the excipient to feed the lactic acid bacteria. By preparing the formulation, the antimicrobial effect can be enhanced and the stability against heat can be overcome.

도 1 은 본 발명에 따른 항균효과가 강화된 사료첨가용 유산균제제의 제조공정을 나타낸 것이다.Figure 1 shows the manufacturing process of the lactic acid bacteria preparation for the enhanced feed antimicrobial effect according to the present invention.

도 2 는 본 발명에 따른 비테인의 화학적 구조를 나타내는 구조식이다.2 is a structural formula showing the chemical structure of bitine according to the present invention.

Claims (5)

통상의 유산균을 배양한 유산균배양에 있어서, In lactic acid bacteria culture which cultured normal lactic acid bacteria, 통상의 유산균을 배양한 배양액에 일정한 온도와 일정한 시간 동안에 일정한 비테인 및 유카추출물을 첨가하여 사균화 유산균 배양액을 제조하는 유산균 배양 및 열처리단계와;Lactic acid bacteria culturing and heat treatment step of producing a bactericidal lactic acid bacteria culture medium by adding a constant bitine and yucca extract at a constant temperature and a predetermined time to the culture medium cultured normal lactic acid bacteria; 상기 열처리가 완료된 사균화 유산균 배양액에 흡착제를 살포하여 흡착시키고 부형제를 혼합한 흡착 및 혼합단계로 이루어진 것을 특징으로 하는 항균효과가 강화된 사료첨가용 유산균제제 조성물 제조방법.The method of producing a lactic acid bacteria composition for feed supplements with enhanced antibacterial effect, characterized in that the adsorbed by spraying the adsorbent to the cultured sterilized lactic acid bacteria culture medium is completed, the adsorbing and mixing step of the excipient. 제1항에 있어서,The method of claim 1, 유산균 배양 및 열처리단계는Lactobacillus culture and heat treatment step 통상의 유산균을 배양한 제1배양액과;A first culture solution in which ordinary lactic acid bacteria are cultured; 상기 제1배양액을 34℃ 내지 37℃에서 일정시간 배양한 후 배양액 1중량부에 대하여 0.005 내지 0.2중량부의 비테인을 첨가하여 60℃ 내지 70℃에서 10분 내지 30분간 열처리 한 다음 34℃ 내지 37℃로 낮춘 제2배양액과;After incubating the first culture solution at 34 ° C. to 37 ° C. for a predetermined time, 0.005 to 0.2 parts by weight of betaine was added to 1 part by weight of the culture solution, followed by heat treatment at 60 ° C. to 70 ° C. for 10 minutes to 30 minutes, and then 34 ° C. to 37 ° C. A second culture solution lowered to ℃; 상기 제2배양액 1중량부에 대하여 0.001 내지 0.05중량부의 유카추출물을 첨가하고 다시 23℃ 내지 37℃에서 일정시간 배양한 제3배양액과;A third culture solution added with 0.001 to 0.05 parts by weight of yucca extract based on 1 part by weight of the second culture solution and incubated at 23 ° C. to 37 ° C. for a predetermined time; 상기 제3배양액 1중량부에 대하여 0.005 내지 0.2중량부의 비테인을 다시 첨가하여 70℃ 내지 80℃에서 10분 내지 30분간 열처리한 다음 34℃ 내지 37℃로 낮 춘 제 4배양액과;A fourth culture solution lowered from 34 ° C. to 37 ° C. after heat treatment at 70 ° C. to 80 ° C. for 10 minutes to 30 minutes, followed by the addition of 0.005 to 0.2 parts by weight of betaine based on 1 part by weight of the third culture solution; 상기 제4배양액 1중량부에 대하여 0.001내지 0.05중량부의 유카추출물을 첨가하고 34℃ 내지 37℃에서 일정시간 배양한 다음 121℃에서 15분 내지 30분간 멸균처리한 제5배양액인 사균화 유산균 배양액인 것을 특징으로 하는 항균효과가 강화된 사료첨가용 유산균제제 조성물 및 그 제조방법.Addition of 0.001 to 0.05 parts by weight of yucca extract per 1 part by weight of the fourth culture solution and incubated for a predetermined time at 34 ℃ to 37 ℃ and sterilized lactic acid bacteria culture medium which is a fifth culture sterilized 15 minutes to 30 minutes at 121 ℃ Lactobacillus formulations for feed supplements, characterized in that the antimicrobial effect is enhanced and a manufacturing method thereof. 제1항에 있어서,The method of claim 1, 흡착 및 혼합단계는 Adsorption and mixing steps 상기 사균화 유산균 배양액 1중량부에 대하여 흡착제 4 내지 9중량부에 흡착하는 흡착단계와;An adsorption step of adsorbing 4 to 9 parts by weight of the adsorbent based on 1 part by weight of the bactericidal lactic acid bacteria culture medium; 상기 사균화 유산균 배양액 흡착물 1중량부에 대하여 통상의 부형제 4 내지 19중량부에 혼합한 것을 특징으로 하는 항균효과가 강화된 사료첨가용 유산균제제 조성물 및 그 제조방법.The antimicrobial effect-enhanced feed additive lactic acid composition and its preparation method characterized in that it is mixed with 4 to 19 parts by weight of the usual excipient with respect to 1 part by weight of the bactericidal lactic acid bacteria culture medium adsorbate. 락토바실루스 아시도필루스(Lactobacillus acidophilus KCTC 3164) 스타터를 MRS 배지에 2%(v/v) 무균적으로 접종한 후 37에서 8시간 배양한 후 멸균 처리한 비테인을 배양액 1중량부에 대하여 0.01중량부 첨가한 후 65℃에서 10분간 1차 열처리하고 37℃로 낮춘 다음, 배양액 1중량부에 대하여 0.01중량부의 멸균 처리한 유카추출물을 첨가하여 37℃에서 8시간 배양한 후 재차 멸균 처리환 비테인을 배양액 1중량부에 대하여 0.01중량부 첨가한 다음 75℃에서 20분간 2차 열처리를 하였 다. 다음, 배양액 1중량부에 대하여 0.01중량부의 멸균 처리한 유카추출물을 다시 첨가하여 37℃에서 8시간 배양한 후 121℃에서 15분간 멸균 처리하여 사균화 유산균 배양액인 것을 특징으로 하는 항균효과가 강화된 사료첨가용 유산균제제 조성물.After aseptically inoculating 2% (v / v) of Lactobacillus acidophilus KCTC 3164 starter in MRS medium and incubating for 8 hours at 37, sterilized bitine was added to 0.01 part by weight of the culture medium. After adding the parts by weight, the first heat treatment at 65 ℃ for 10 minutes and lowered to 37 ℃, and then added 0.01 parts by weight of sterilized yucca extract to 1 part by weight of the culture and incubated for 8 hours at 37 ℃ and then again sterilized Phosphorus was added 0.01 part by weight based on 1 part by weight of the culture medium, followed by secondary heat treatment at 75 ° C. for 20 minutes. Next, 0.01 parts by weight of the sterilized yucca extract was added to 1 part by weight of the culture medium, incubated for 8 hours at 37 ° C., and sterilized for 15 minutes at 121 ° C. to enhance the antibacterial effect of the cultured lactic acid bacteria. Lactic acid bacteria composition for feed addition. 제4항에 있어서,The method of claim 4, wherein 상기 사균화 유산균배양액 1중량부에 대하여 7중량부의 제올라이트를 혼합기에 넣고 30RPM속도로 교반하면서 사균화 유산균 배양액을 분사하여 사균화 유산균 배양액 흡착물을 제조한 다음, 사균화 유산균 배양액 흡착물 1중량부에 대하여 12중량부의 왕겨분을 혼합기내에 추가하여 35RPM속도로 15분간 혼합하여 조성된 사료첨가용 유산균제제인 것을 특징으로 하는 항균효과가 강화된 사료첨가용 유산균제제 조성물.7 parts by weight of zeolite per 1 part by weight of the bactericidal lactic acid bacteria culture medium was added to the mixer, and the mixture of the bactericidal Lactobacillus culture medium was prepared by spraying the bactericidal Lactobacillus culture medium while stirring at 30 RPM, and then 1 part by weight of the bactericidal Lactobacillus culture medium adsorbate. Addition of 12 parts by weight of rice hull powder into the mixer for mixing for 15 minutes at 35 RPM speed was added to the lactic acid bacteria formulation for enhanced feed antimicrobial effect, characterized in that the composition was added.
KR1020080003847A 2008-01-14 2008-01-14 The composition of improved Lactic acid bacteria feed additive and Method for manufacturing thereof KR100923226B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020080003847A KR100923226B1 (en) 2008-01-14 2008-01-14 The composition of improved Lactic acid bacteria feed additive and Method for manufacturing thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020080003847A KR100923226B1 (en) 2008-01-14 2008-01-14 The composition of improved Lactic acid bacteria feed additive and Method for manufacturing thereof

Publications (2)

Publication Number Publication Date
KR20090078065A true KR20090078065A (en) 2009-07-17
KR100923226B1 KR100923226B1 (en) 2009-10-27

Family

ID=41336257

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020080003847A KR100923226B1 (en) 2008-01-14 2008-01-14 The composition of improved Lactic acid bacteria feed additive and Method for manufacturing thereof

Country Status (1)

Country Link
KR (1) KR100923226B1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102001424B1 (en) 2019-04-23 2019-07-18 정광천 Restoring apparatus for crushed parts of a paper egg plate
KR102334386B1 (en) * 2021-01-22 2021-12-01 김향숙 Manufacturing method of functional feed for odor reduction

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101425712B1 (en) 2012-06-21 2014-07-31 일동제약주식회사 Method of tynadallized Lactobacillus acidophilus
KR102567095B1 (en) 2021-09-15 2023-08-16 대한민국 Novel Lactobacillus sp. strain isolated from Sorbaria sorbifolia var. stellipila Maxim.
KR102629608B1 (en) * 2021-09-27 2024-02-01 주식회사 일위 Antibacterial composition comprising a fractional extract isolated from Coturnix japonica eggs as an active ingredient
WO2023054790A1 (en) * 2021-09-28 2023-04-06 을지대학교 산학협력단 Antiviral composition comprising, as active ingredient, fractional extract isolated from coturnix japonica eggs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR200261352Y1 (en) * 2001-10-06 2002-01-24 주식회사 플러스매니저 Mechanical Seal Structure
KR200410830Y1 (en) * 2005-12-30 2006-03-08 주식회사 수성엔지니어링 Railroad tie for smooth ground

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102001424B1 (en) 2019-04-23 2019-07-18 정광천 Restoring apparatus for crushed parts of a paper egg plate
KR102334386B1 (en) * 2021-01-22 2021-12-01 김향숙 Manufacturing method of functional feed for odor reduction

Also Published As

Publication number Publication date
KR100923226B1 (en) 2009-10-27

Similar Documents

Publication Publication Date Title
Markowiak et al. The role of probiotics, prebiotics and synbiotics in animal nutrition
Stavric et al. 10 Microbial probiotics for pigs and poultry
Jin et al. Influence of dried Bacillus substillis and lactobacilli cultures on intestinal microflora and performance in broilers
Ahmed et al. Evaluation of Lactobacillus and Bacillus-based probiotics as alternatives to antibiotics in enteric microbial challenged weaned piglets
CN103392911B (en) Feed-use high-activity lactobacillus solid preparation and preparation method thereof
Cromwell Antimicrobial and promicrobial agents
US20130243908A1 (en) Monogastric animal feed
Beck et al. The potential for inoculating Lactobacillus animalis and Enterococcus faecium alone or in combination using commercial in ovo technology without negatively impacting hatch and post-hatch performance
CN103005159A (en) Preparation method of ginkgo leaf biological feed additive
Deniz et al. Effects of probiotic (Bacillus subtilis DSM 17299) supplementation on the caecal microflora and performance in broiler chickens
CN107484879A (en) Feed addictive, antibiotic-free feed and its application
KR100923226B1 (en) The composition of improved Lactic acid bacteria feed additive and Method for manufacturing thereof
RU2458526C1 (en) Probiotic fodder additive for farm birds and fur animals
WO1993002558A1 (en) Method and formulation for reducing microbial populations
WO1995007090A1 (en) Probiotics
Vinolya et al. Effect of dietary supplementation of acidifiers and essential oils on growth performance and intestinal health of broiler
Tesfaye et al. The effects of probiotics supplementation on milk yield and composition of lactating dairy cows
Iegorov et al. Probiotic feed additives in fattening of agricultural animals
CA2100774C (en) Feed additive and method
US20140037605A1 (en) Anticoccidial composition
Sharma et al. Probiotic supplementation in the diet of rabbits—A Review
KR20140065224A (en) Composition for eco-friendly microorganism formulation comprising microorganism probiotics as effective ingredient and production method thereof
CN102334610A (en) Antibiotic-free environment-friendly biological feed and production method thereof
CN111821322A (en) Poultry micro-ecological oral preparation capable of replacing antibiotics and application thereof
CN111084155A (en) Healthy breeding method for effectively preventing and controlling swine fever

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120725

Year of fee payment: 4

FPAY Annual fee payment

Payment date: 20130903

Year of fee payment: 5

FPAY Annual fee payment

Payment date: 20141015

Year of fee payment: 6

FPAY Annual fee payment

Payment date: 20160819

Year of fee payment: 8

FPAY Annual fee payment

Payment date: 20180827

Year of fee payment: 10

FPAY Annual fee payment

Payment date: 20190813

Year of fee payment: 11